BLIS Technologies Limited (NZSE: BLT)
Health Care · Pharmaceuticals · NZ
NZ$0.02
+5.56% today · +5.6% 1Y
BLIS Technologies Limited (NZSE: BLT) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $14.52M and employs 43 people.
Over the last twelve months the share price has gained 5.6%, trading between 0.01 and 0.02.
Tweenvest scores BLIS Technologies Limited across four factors: quality 74/100, value 43/100, growth 61/100. Its strongest factor is quality.
BLT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $14.52M
- Revenue (TTM)
- $8.41M
- P/E
- 38.00
- EPS
- 0.00
- Dividend yield
- —
- Beta (5Y)
- 0.64
- 52-week high
- NZ$0.02
- 52-week low
- NZ$0.01
- Avg volume (3M)
- —
- Shares outstanding
- 1.28B
- Employees
- 43
- Next earnings
- —
About BLIS Technologies Limited
BLIS Technologies Limited, together with its subsidiaries, specializes in creating and distributing health-focused products. These offerings are underpinned by unique bacterial strains that exhibit bacteriocin activity. The company prominently features several key probiotic strains: BLIS K12, a supplement engineered to bolster ear, nose, and throat well-being in young children, in addition to enhancing immune function and combating halitosis; BLIS M18, an oral probiotic designed to promote robust dental and gum health; and BLIS Q24, a probiotic formulation aimed at harmonizing and rejuvenating the skin's microbiome, thereby fostering healthier, clearer, and more radiant skin. Established in 2000, BLIS Technologies is based in Dunedin, New Zealand, and maintains a global presence with operations spanning New Zealand, the Asia Pacific region, Europe, the Middle East, Africa, and North America.
- ISIN
- NZBLTE0002S8
- Founded
- 2000
- Listed since
- Jul 29, 2001
- Exchange
- New Zealand Stock Exchange
- Currency
- NZD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,198.00 | -2.89% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.78 | -0.86% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.99 | -1.57% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.42 | -0.54% |
Figures last refreshed Aug 18, 2026.